For various psychiatric diseases and symptoms, many clinical trials of rTMS (repetitive transcranial magnetic stimulation) treatment have been conducted. However, most of them were for depression, and meta- analyses were reported only for auditory hallucinations and positive/negative symptoms in schizophrenia and OCD (obsessive- compulsive disorder) as well as depression. In treating depression, rTMS shows lower efficacy and slower response time but higher tolerability compared with ECT (electroconvulsive therapy), and some studies reported comparable benefit of rTMS to antidepressant medications. For treating severely depressed patients, the US Food and Drug Administration approved an rTMS device under several strict conditions in 2008, and we are expecting increase of successfully treated patients and elucidation of the therapeutic mechanisms of rTMS. The meta- analyses show favorable therapeutic effects on auditory hallucinations, but do not show any significant therapeutic effects on positive/negative symptoms in schizophrenia and OCD.